Form 4: Bolt Biotherapeutics VP Acquires Stock Options

Sarah Nemec, VP of Finance and PAO at Bolt Biotherapeutics, acquired stock options for 140,000 shares on July 23, 2024.

Summary

• Sarah Nemec, VP of Finance and PAO at Bolt Biotherapeutics, filed a Form 4 on July 24, 2024.
• The filing reports the acquisition of stock options to purchase 50,000 shares of common stock at an exercise price of $0.7301 on July 23, 2024.
• These options vest monthly over 36 months starting July 15, 2024, contingent upon continuous service.
• Additionally, Nemec acquired options to purchase 90,000 shares of common stock at an exercise price of $0.7301 on July 23, 2024.
• These options vest on July 15, 2025, contingent upon continuous service.
• The options expire on July 22, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to executive compensation. The acquisition of stock options can be seen as a positive sign, but it's not a major event.

Positives

• The acquisition of stock options by a company executive can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a typical component of compensation packages for executives in biotech companies like Bolt Biotherapeutics.
• Companies such as Amgen, Gilead Sciences, and Biogen also utilize stock options to incentivize their leadership teams.
• The vesting schedules and exercise prices are generally aligned with industry norms to retain and motivate key personnel.

Stakeholder Impact

• The granting of stock options could potentially dilute existing shareholders' equity if the options are exercised.

Key Dates